{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T08:17:38Z","timestamp":1783153058399,"version":"3.54.6"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["L246069"],"award-info":[{"award-number":["L246069"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.pharmthera.2026.109039","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:36:18Z","timestamp":1777527378000},"page":"109039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Current drug treatment methods and potential significance of glucocorticoid for inoperable advanced thymoma"],"prefix":"10.1016","volume":"284","author":[{"given":"Xin-tao","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-guo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-dian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pharmthera.2026.109039_bb0005","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.immuni.2020.08.005","article-title":"Endogenous glucocorticoid signaling regulates CD8+ T cell differentiation and development of dysfunction in the tumor microenvironment","volume":"53","author":"Acharya","year":"2020","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109039_bb0010","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.it.2012.03.005","article-title":"Thymic epithelial cells: Working class heroes for T cell development and repertoire selection","volume":"33","author":"Anderson","year":"2012","journal-title":"Trends in Immunology"},{"key":"10.1016\/j.pharmthera.2026.109039_bb0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2022.07.009","article-title":"Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group","volume":"174","author":"Antonarelli","year":"2022","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109039_bb0020","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12943-023-01772-4","article-title":"Immunotherapy of thymic epithelial tumors: Molecular understandings and clinical perspectives","volume":"22","author":"Ao","year":"2023","journal-title":"Molecular Cancer"},{"key":"10.1016\/j.pharmthera.2026.109039_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.583781","article-title":"Case report: Lymphocytosis associated with fatal hepatitis in a thymoma patient treated with anti-PD1: New insight into the immune-related storm","volume":"10","author":"Argentiero","year":"2020","journal-title":"Frontiers in Oncology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109039_bb0030","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1084\/jem.20011629","article-title":"In vitro generation of interleukin 10\u2013producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)\u2013and Th2-inducing cytokines","volume":"195","author":"Barrat","year":"2002","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2026.109039_bb0035","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1016\/0959-8049(93)91606-L","article-title":"Neoadjuvant chemotherapy with adriamycin, cisplatin, vincristine and ciclophosphamide (ADOC) in invasive thymomas, preliminary results","volume":"29","author":"Berruti","year":"1993","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2026.109039_bb0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.lungcan.2016.06.020","article-title":"Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience","volume":"99","author":"Bluthgen","year":"2016","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109039_bb0050","article-title":"Aberrant peripheral immune function in a good syndrome patient","volume":"2018","author":"Chen","year":"2018","journal-title":"Journal of Immunology Research"},{"issue":"24","key":"10.1016\/j.pharmthera.2026.109039_bb0055","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: An open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"21","key":"10.1016\/j.pharmthera.2026.109039_bb0060","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1073\/pnas.89.21.9991","article-title":"A mechanism for the antiinflammatory effects of corticosteroids: The glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1","volume":"89","author":"Cronstein","year":"1992","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109039_bb0065","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.jtho.2018.08.005","article-title":"Systemic therapy in advanced thymic epithelial tumors: Insights from the RYTHMIC prospective cohort","volume":"13","author":"Du Vignaux","year":"2018","journal-title":"Journal of Thoracic Oncology"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109039_bb0070","doi-asserted-by":"crossref","first-page":"13408","DOI":"10.1002\/cam4.6043","article-title":"Risk factor analysis of thymoma resection and its value in guiding clinical treatment","volume":"12","author":"Du","year":"2023","journal-title":"Cancer Medicine"},{"key":"10.1016\/j.pharmthera.2026.109039_bb0075","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3389\/fimmu.2019.02028","article-title":"More than suppression: Glucocorticoid action on monocytes and macrophages","volume":"10","author":"Ehrchen","year":"2019","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109039_bb0080","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1196\/annals.1321.010","article-title":"Glucocorticoids and the Th1\/Th2 balance","volume":"1024","author":"Elenkov","year":"2004","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109039_bb0085","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jtho.2022.10.016","article-title":"Surgical, radiation, and systemic treatments of patients with thymic epithelial tumors: A systematic review","volume":"18","author":"Falkson","year":"2023","journal-title":"Journal of Thoracic Oncology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109039_bb0090","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1470-2045(07)70141-9","article-title":"Response of thymoma to cetuximab","volume":"8","author":"Farina","year":"2007","journal-title":"The Lancet Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109039_bb0095","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4","article-title":"Chemotherapy for invasive thymoma. A 13-year experience","volume":"68","author":"Fornasiero","year":"1991","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109039_bb0100","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s00432-004-0646-8","article-title":"Glucocorticoids induce G1 cell cycle arrest in human neoplastic thymic epithelial cells","volume":"131","author":"Funakoshi","year":"2005","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2026.109039_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.08.003","article-title":"The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers","volume":"79","author":"Gelsomino","year":"2019","journal-title":"Cancer Treatment Reviews"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109039_bb0110","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.1996.14.3.814","article-title":"Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer lung Cancer cooperative group","volume":"14","author":"Giaccone","year":"1996","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109039_bb0115","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"The Lancet Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109039_bb0120","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40425-018-0371-5","article-title":"Dexamethasone-induced immunosuppression: Mechanisms and implications for immunotherapy","volume":"6","author":"Giles","year":"2018","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109039_bb0130","doi-asserted-by":"crossref","first-page":"S1749","DOI":"10.1097\/JTO.0b013e31821ea5f7","article-title":"Chemotherapy definitions and policies for thymic malignancies","volume":"6","author":"Girard","year":"2011","journal-title":"Journal of Thoracic Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109039_bb0135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/JTO.0b013e31818e105c","article-title":"Thymoma: A focus on current therapeutic management","volume":"4","author":"Girard","year":"2009","journal-title":"Journal of Thoracic Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109039_bb0140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF01966828","article-title":"Influence of glucocorticoids on histamine release and 45calcium uptake by isolated rat mast cells","volume":"14","author":"Grosman","year":"1984","journal-title":"Agents and Actions"},{"issue":"3. 4","key":"10.1016\/j.pharmthera.2026.109039_bb0145","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2152\/jmi.68.396","article-title":"A rare case of invasive thymoma presented a dramatic response to low-dose prednisolone as a single-drug therapy","volume":"68","author":"Hanibuchi","year":"2021","journal-title":"The Journal of Medical Investigation"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109039_bb0150","doi-asserted-by":"crossref","first-page":"9452","DOI":"10.3390\/curroncol29120743","article-title":"Comparison of efficacy and safety of platinum-based chemotherapy as first-line therapy between B3 thymoma and thymic carcinoma","volume":"29","author":"Hao","year":"2022","journal-title":"Current Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109039_bb0155","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S1658-3876(09)50022-2","article-title":"Multimodality treatments in locally advanced stage thymomas","volume":"2","author":"Hassan","year":"2009","journal-title":"Hematology\/Oncology and Stem Cell Therapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109039_bb0160","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(17)30239-5","article-title":"Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN solid tumor): A phase 1a, multicohort, dose-escalation trial","volume":"18","author":"Heery","year":"2017","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2026.109039_bb0165","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.lungcan.2020.09.006","article-title":"Everolimus in the treatment of metastatic thymic epithelial tumors","volume":"149","author":"Hellyer","year":"2020","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109039_bb0170","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.21037\/cdt-21-147","article-title":"Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia gravis\u2014A case report","volume":"11","author":"Hern\u00e1ndez","year":"2021","journal-title":"Cardiovascular Diagnosis and Therapy"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109039_bb0175","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.1999.17.9.2737","article-title":"Treatment of invasive thymoma with single-agent ifosfamide","volume":"17","author":"Highley","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109039_bb0180","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev-immunol-101320-022432","article-title":"Instructive cues of thymic T cell selection","volume":"40","author":"Irla","year":"2022","journal-title":"Annual Review of Immunology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109039_bb0185","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3390\/cells11050770","article-title":"Impact of glucocorticoid use in oncology in the immunotherapy era","volume":"11","author":"Kalfeist","year":"2022","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109039_bb0190","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.jaci.2004.07.014","article-title":"Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma","volume":"114","author":"Karagiannidis","year":"2004","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109039_bb0195","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2015.03.003","article-title":"Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma","volume":"88","author":"Katsuya","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.pharmthera.2026.109039_bb9098","article-title":"Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review","volume":"6493\u2013101","author":"Khan","year":"2020","journal-title":"Semin Cancer Biol."},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109039_bb0200","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2003.12.010","article-title":"Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas","volume":"44","author":"Kim","year":"2004","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109039_bb0205","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1097\/00000478-199212000-00003","article-title":"Well-differentiated thymic carcinoma: An organotypical low-grade carcinoma with relationship to cortical thymoma","volume":"16","author":"Kirchner","year":"1992","journal-title":"The American Journal of Surgical Pathology"},{"issue":"1,2","key":"10.1016\/j.pharmthera.2026.109039_bb0210","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2152\/jmi.55.17","article-title":"Optimal therapy for thymoma","volume":"55","author":"Kondo","year":"2008","journal-title":"The Journal of Medical Investigation"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109039_bb0215","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: A clinical study of 1,320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"The Annals of Thoracic Surgery"},{"key":"10.1016\/j.pharmthera.2026.109039_bb0220","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.lungcan.2019.06.015","article-title":"Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review","volume":"135","author":"Konstantina","year":"2019","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109039_bb0225","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.bjc.6605731","article-title":"A phase II trial of dose-dense chemotherapy, followed by surgical resection and\/or thoracic radiotherapy, in locally advanced thymoma: Report of a Japan clinical oncology group trial (JCOG 9606)","volume":"103","author":"Kunitoh","year":"2010","journal-title":"British Journal of Cancer"},{"issue":"6349","key":"10.1016\/j.pharmthera.2026.109039_bb0230","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.pharmthera.2026.109039_bb0235","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109039_bb0240","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.lungcan.2014.11.006","article-title":"Pemetrexed in patients with thymic malignancies previously treated with chemotherapy","volume":"87","author":"Liang","year":"2015","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109039_bb0245","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.1997.15.9.3093","article-title":"Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: An intergroup trial","volume":"15","author":"Loehrer","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109039_bb0250","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2","article-title":"Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: An intergroup trial","volume":"91","author":"Loehrer","year":"2001","journal-title":"Cancer: Interdisciplinary International Journal of the American Cancer Society"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109039_bb0255","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: Final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group","volume":"12","author":"Loehrer","year":"1994","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109039_bb0260","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2004.02.047","article-title":"Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: An eastern cooperative oncology group phase II trial","volume":"22","author":"Loehrer","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109039_bb0265","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/COC.0b013e318209a8f8","article-title":"Efficacy and tolerability of long-acting octreotide in the treatment of thymic tumors: Results of a pilot trial","volume":"35","author":"Longo","year":"2012","journal-title":"American Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109039_bb0270","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005747","article-title":"Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies: Three case reports","volume":"96","author":"Lu","year":"2017","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109039_bb0275","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/1097-0142(19910815)68:4<706::AID-CNCR2820680407>3.0.CO;2-H","article-title":"Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma","volume":"68","author":"Macchiarini","year":"1991","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109039_bb0280","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jtho.2021.10.010","article-title":"The 2021 WHO classification of tumors of the thymus and mediastinum: What is new in thymic epithelial, germ cell, and mesenchymal tumors?","volume":"17","author":"Marx","year":"2022","journal-title":"Journal of Thoracic Oncology"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109039_bb0285","doi-asserted-by":"crossref","first-page":"7864","DOI":"10.3390\/ijms23147864","article-title":"Unraveling the immune microenvironment of thymic epithelial tumors: Implications for autoimmunity and treatment","volume":"23","author":"Masaoutis","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109039_bb0290","doi-asserted-by":"crossref","first-page":"6062","DOI":"10.1038\/ncomms7062","article-title":"Glucocorticoids suppress inflammation via the upregulation of negative regulator IRAK-M","volume":"6","author":"Miyata","year":"2015","journal-title":"Nature Communications"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109039_bb0295","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004699","article-title":"Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: Proof of concept","volume":"10","author":"Nguyen","year":"2022","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109039_bb0300","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3390\/jpm12060888","article-title":"CD21lo B cells could be a potential predictor of immune-related adverse events in renal cell carcinoma","volume":"12","author":"Nishimura","year":"2022","journal-title":"Journal of Personalized Medicine"},{"key":"10.1016\/j.pharmthera.2026.109039_bb0305","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00432-014-1800-6","article-title":"Key components of chemotherapy for thymic malignancies: A systematic review and pooled analysis for anthracycline-, carboplatin-or cisplatin-based chemotherapy","volume":"141","author":"Okuma","year":"2015","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109039_bb0310","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jtho.2018.04.013","article-title":"Expression patterns, prognostic value, and intratumoral heterogeneity of PD-L1 and PD-1 in thymoma and thymic carcinoma","volume":"13","author":"Owen","year":"2018","journal-title":"Journal of Thoracic Oncology"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109039_bb0315","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.2217\/fon.14.144","article-title":"Capecitabine plus gemcitabine in thymic epithelial tumors: Final analysis of a phase II trial","volume":"10","author":"Palmieri","year":"2014","journal-title":"Future Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109039_bb0320","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2741\/2098","article-title":"Cetuximab is an active treatment of metastatic and chemorefractory thymoma (648 views)","volume":"12","author":"Palmieri","year":"2007","journal-title":"Frontiers in Bioscience"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109039_bb0325","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/annonc\/mdp483","article-title":"Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs)","volume":"21","author":"Palmieri","year":"2010","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109039_bb0330","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nature Reviews Cancer"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109039_bb0340","doi-asserted-by":"crossref","first-page":"S361","DOI":"10.1097\/JTO.0b013e3181f21114","article-title":"Targeted therapy for advanced thymic tumors","volume":"5","author":"Rajan","year":"2010","journal-title":"Journal of Thoracic Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109039_bb0345","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.thorsurg.2010.08.003","article-title":"Chemotherapy for thymic tumors: Induction, consolidation, palliation","volume":"21","author":"Rajan","year":"2011","journal-title":"Thoracic Surgery Clinics"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109039_bb0350","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","article-title":"Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma","volume":"7","author":"Rajan","year":"2019","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.pharmthera.2026.109039_bb0355","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.lungcan.2016.04.024","article-title":"Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network","volume":"97","author":"Remon","year":"2016","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109039_bb0360","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1016\/j.cllc.2021.07.008","article-title":"PECATI: A multicentric, open-label, single-arm phase II study to evaluate the efficacy and safety of pembrolizumab and lenvatinib in pretreated B3-thymoma and thymic carcinoma patients","volume":"23","author":"Remon","year":"2022","journal-title":"Clinical Lung Cancer"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109039_bb0365","doi-asserted-by":"crossref","first-page":"S323","DOI":"10.1097\/JTO.0b013e3181f20e90","article-title":"Induction therapy for locally advanced thymoma","volume":"5","author":"Riely","year":"2010","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.pharmthera.2026.109039_bb0370","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40364-019-0177-8","article-title":"Immune biomarkers in thymic epithelial tumors: Expression patterns, prognostic value and comparison of diagnostic tests for PD-L1","volume":"7","author":"Rouquette","year":"2019","journal-title":"Biomarker Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109039_bb0375","doi-asserted-by":"crossref","first-page":"S357","DOI":"10.1097\/JTO.0b013e3181f21129","article-title":"The role of chemotherapy in advanced thymoma","volume":"5","author":"Schmitt","year":"2010","journal-title":"Journal of Thoracic Oncology"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109039_bb0385","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1002\/jcp.26429","article-title":"Macrophage plasticity, polarization, and function in health and disease","volume":"233","author":"Shapouri-Moghaddam","year":"2018","journal-title":"Journal of Cellular Physiology"},{"key":"10.1016\/j.pharmthera.2026.109039_bb0390","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.621858","article-title":"Immune-therapy-related toxicity events and dramatic remission after a single dose of pembrolizumab treatment in metastatic thymoma: A case report","volume":"12","author":"Shen","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2026.109039_bb0395","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jns.2019.02.023","article-title":"PD-1 inhibitor-associated severe myasthenia gravis with necrotizing myopathy and myocarditis","volume":"399","author":"So","year":"2019","journal-title":"Journal of the Neurological Sciences"},{"issue":"200","key":"10.1016\/j.pharmthera.2026.109039_bb0400","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Science Translational Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109039_bb0405","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1078-0432.CCR-07-1786","article-title":"A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors","volume":"14","author":"Steele","year":"2008","journal-title":"Clinical Cancer Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109039_bb0410","doi-asserted-by":"crossref","first-page":"S286","DOI":"10.1097\/JTO.0b013e3181f209a8","article-title":"Thymoma and thymic carcinoma: Molecular pathology and targeted therapy","volume":"5","author":"Str\u00f6bel","year":"2010","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.pharmthera.2026.109039_bb0420","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s004280000333","article-title":"Histopathologic changes of thymoma preoperatively treated with corticosteroids","volume":"438","author":"Tateyama","year":"2001","journal-title":"Virchows Archiv"},{"key":"10.1016\/j.pharmthera.2026.109039_bb0425","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.canlet.2017.11.014","article-title":"Progress and challenges of predictive biomarkers of anti PD-1\/PD-L1 immunotherapy: A systematic review","volume":"414","author":"Teng","year":"2018","journal-title":"Cancer Letters"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109039_bb0430","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: An open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2026.109039_bb0435","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12865-015-0103-2","article-title":"Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: An insight into the optimum application of glucocorticoids in anti-cancer therapy","volume":"16","author":"Xing","year":"2015","journal-title":"BMC Immunology"},{"issue":"Suppl. 13","key":"10.1016\/j.pharmthera.2026.109039_bb0450","doi-asserted-by":"crossref","first-page":"S1509","DOI":"10.21037\/jtd.2017.10.157","article-title":"Thymic tumors and immune checkpoint inhibitors","volume":"10","author":"Yokoyama","year":"2018","journal-title":"Journal of Thoracic Disease"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109039_bb0455","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/1759-7714.13362","article-title":"Evaluating the effectiveness of chemotherapy for thymic epithelial tumors using the CD-DST method","volume":"11","author":"Yu","year":"2020","journal-title":"Thoracic Cancer"},{"key":"10.1016\/j.pharmthera.2026.109039_bb0460","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41435-025-00329-3","article-title":"Novel modulation of T effector memory cells-expressing CD45RA by prednisone in inoperable advanced type B thymoma patients","volume":"26","author":"Yu","year":"2025","journal-title":"Genes & Immunity"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109039_bb0465","doi-asserted-by":"crossref","DOI":"10.21037\/apm-21-943","article-title":"A case report of advanced thymoma re-treated with PD-1 inhibitor after initial immune-related pneumonitis","volume":"10","author":"Zhang","year":"2021","journal-title":"Annals of Palliative Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109039_bb0470","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.7039","article-title":"Myocarditis and myasthenia gravis induced by immune checkpoint inhibitor in a patient with relapsed thymoma: A case report","volume":"11","author":"Zhong","year":"2023","journal-title":"Clinical Case Reports"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109039_bb0475","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s13760-021-01731-0","article-title":"The effect of glucocorticoids on radiology and histology of thymoma in myasthenia gravis","volume":"122","author":"Zouvelou","year":"2022","journal-title":"Acta Neurologica Belgica"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109039_bb0480","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy","volume":"36","author":"Zucali","year":"2018","journal-title":"Journal of Clinical Oncology"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826000665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826000665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T07:41:02Z","timestamp":1783150862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725826000665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":90,"alternative-id":["S0163725826000665"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109039","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current drug treatment methods and potential significance of glucocorticoid for inoperable advanced thymoma","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109039"}}